The fourth in this week’s series, building on earlier pieces, brings the focus squarely onto the PBS, arguing that spending on medicines has not truly slowed, but has shifted decisively from government to consumers, reshaping how the PBS functions, what it can fund, and the policy choices now confronting decision-makers.
The PBS paradox - a rising medicine spend, but a shrinking investment capacity
January 20, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
ARCS evolves into LifeSciences Australia as part of wider strategic change
June 11, 2026 - - Latest News -
Sigma confirms interest in the acquisition of UK pharmacy chain Boots
June 10, 2026 - - Latest News -
Island secures US partnership to advance Galidesivir dose study for Marburg
June 10, 2026 - - Australian Biotech -
Cartherics secures Japanese patent to bolster cell therapy push
June 10, 2026 - - Australian Biotech -
GSK to buy Nuvalent in a major move to acquire rights to late stage lung cancer candidates
June 10, 2026 - - Latest News -
Australian company secures US fast track for CAR-T in blood cancers
June 10, 2026 - - Latest News -
Industry campaign highlights MFN risk to US jobs and the broader economy
June 10, 2026 - - Latest News

